Bausch Health Companies (NYSE:BHC – Get Rating) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Tuesday.
A number of other equities analysts have also recently issued reports on BHC. TD Cowen cut Bausch Health Companies from an “outperform” rating to a “market perform” rating in a report on Friday, June 16th. Jefferies Financial Group upped their price objective on Bausch Health Companies from $7.00 to $9.50 in a report on Monday, May 22nd. Six research analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $7.83.
Bausch Health Companies Price Performance
BHC stock opened at $7.28 on Tuesday. The company has a debt-to-equity ratio of 139.36, a current ratio of 1.08 and a quick ratio of 0.77. Bausch Health Companies has a one year low of $4.00 and a one year high of $10.23. The stock has a market cap of $2.64 billion, a PE ratio of -7.43, a P/E/G ratio of 0.11 and a beta of 0.95. The firm has a 50 day simple moving average of $7.33 and a two-hundred day simple moving average of $7.61.
Bausch Health Companies (NYSE:BHC – Get Rating) last released its quarterly earnings results on Thursday, May 4th. The company reported $0.52 EPS for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.23). Bausch Health Companies had a positive return on equity of 381.67% and a negative net margin of 4.38%. The company had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.95 billion. On average, analysts predict that Bausch Health Companies will post 3.26 EPS for the current fiscal year.
Institutional Trading of Bausch Health Companies
A number of institutional investors have recently made changes to their positions in BHC. Elliott Investment Management L.P. bought a new stake in Bausch Health Companies in the 3rd quarter worth $101,000. Polar Asset Management Partners Inc. purchased a new stake in shares of Bausch Health Companies during the third quarter worth about $344,000. ExodusPoint Capital Management LP purchased a new stake in shares of Bausch Health Companies during the third quarter worth about $234,000. Pendal Group Ltd boosted its holdings in shares of Bausch Health Companies by 952.3% during the fourth quarter. Pendal Group Ltd now owns 858,684 shares of the company’s stock worth $5,391,000 after purchasing an additional 777,084 shares during the period. Finally, Financial Freedom LLC purchased a new stake in shares of Bausch Health Companies during the fourth quarter worth about $194,000. Hedge funds and other institutional investors own 74.38% of the company’s stock.
Bausch Health Companies Company Profile
Bausch Health Companies Inc operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.